Advancing perioperative care in MIBC: insights from NIAGARA
Status Publisher Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
39994443
DOI
10.1038/s41585-025-01009-7
PII: 10.1038/s41585-025-01009-7
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Semmelweis University Budapest Hungary
Department of Urology The University of Texas Southwestern Medical Center at Dallas Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Division of Urology Department of Special Surgery The University of Jordan Amman Jordan
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Zobrazit více v PubMed
Porter, M. P., Kerrigan, M. C., Donato, B. M. K. & Ramsey, S. D. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol. Oncol. 29, 252–258 (2011). PubMed DOI
Yin, M. et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist 21, 708–715 (2016). PubMed DOI PMC
Powles, T. et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N. Engl. J. Med. 391, 1773–1786 (2024). PubMed DOI
Galsky, M. D. et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Rep. Med. 5, 101393 (2024). PubMed DOI PMC
Sritharan, S. & Sivalingam, N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 278, 119527 (2021). PubMed DOI
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021). PubMed DOI PMC
Larkins, E. A phase III study of neoadjuvant/adjuvant durvalumab for the treatment of patients with resectable stage II/III non-small cell lung cancer (AEGEAN): contribution of treatment phase in perioperative trials (FDA, 2024).
Sammarco, E. et al. Immune checkpoint inhibitor rechallenge in renal cell carcinoma: current evidence and future directions. Cancers 15, 3172 (2023). PubMed DOI PMC
